ArticleBMC pediatrics2025
Evaluation of potential drug-drug interactions in the neonatal intensive care unit with two different decision support software: a retrospective study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prescription of vitamin D in neonates and infants under one year of age in Spain: an eight-year observational study.BMC primary care · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-drug interactions (DDIs) are a critical concern in neonatal intensive care units (NICUs) due to polypharmacy and the physiological vulnerability of neonates. This study aims to evaluate potential DDIs (pDDIs) using two different decision support software (DSS), Lexidrug™ and Micromedex
methodsThis retrospective study included neonates admitted to a tertiary NICU between January 1, 2022, and January 1, 2023, who received at least two systemically administered medications and stayed for ≥ 24 h. Patients with missing prescriptions or readmissions were excluded. pDDIs were assessed using two different DSS: Lexidrug™ and Micromedex
resultsThe study included 280 patients. The gestational age median (interquartile range [IQR]) was 36 (34-38) weeks, and birth weight median (IQR) was 2745 (2181.2-3250) g. According to Lexidrug™ and Micromedex
conclusionpDDIs were detected in a significant proportion of patients in the NICU. This study revealed weak agreement between different DSS used to assess pDDIs in the NICU. The findings underscore the importance of collaboration between clinical pharmacists and neonatologists when interpreting DSS results. Further prospective, multicenter cohort studies are warranted to validate these findings and improve DDI management strategies in neonatal populations.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.